The Trump administration proposes a new rule intended to reduce drug costs for Medicare patients by limiting how hospitals handle discounted medications. According to reporting from multiple outlets, the proposal targets the practice of hospitals “marking up” certain discounted drugs when billing Medicare, rather than passing the reduced price to patients. The administration says the rule could save Medicare beneficiaries about $1.1 billion on prescription drugs, though details of projected savings depend on how the rule is implemented and applied.
The rule would focus on hospitals’ billing and reimbursement practices involving discounted drugs, with the stated goal of ensuring Medicare patients benefit from discounts rather than seeing those discounts reduced through markups. The proposed change is positioned as a cost-savings measure within Medicare’s drug reimbursement system.
The outlets provide the same basic description of the proposal and the stated savings figure, though neither summary includes specific legal mechanisms, scope by drug type, or expected timeline for finalizing and enforcing the rule.
